I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
The PCN recommends tofactinib as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA480.
Prescribing will be by hospital specialists only, in line with NICE TA480 using Blueteq initiation and continuation forms. Tofacitinib will be considered RED on the traffic light system.
